Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension.
about
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction RiskCan proteomics yield insight into aging aorta?Moderate Dietary Supplementation with Omega-3 Fatty Acids Does Not Impact Plasma Von Willebrand Factor Profile in Mildly Hypertensive SubjectsPlatelet abnormalities in chronic thromboembolic pulmonary hypertension.Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African AmericansTelmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.Sustained release of prindopril erbumine from its chitosan-coated magnetic nanoparticles for biomedical applications.Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.Impact of telmisartan in modifying vascular risk.Association of ambulatory arterial stiffness index with sEPCR in newly diagnosed hypertensive patients.Decreased Activity of the Protein C Anticoagulant Pathway in the Early Hours of Paroxysmal Atrial Fibrillation.The Development and Validation of a Stability-Indicating UHPLC-DAD Method for Determination of Perindopril l-Arginine in Bulk Substance and Pharmaceutical Dosage Form.Perindopril for improving cardiovascular events.Long-term treatment with ramipril favourably modifies the haemostatic response to acute submaximal exercise in hypertensives.Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.Novel pseudopolymorph of the active metabolite of perindopril.Controlled-release formulation of perindopril erbumine loaded PEG-coated magnetite nanoparticles for biomedical applications
P2860
Q28076223-AED38E9C-31B5-48C5-B8F2-E09378FC3B0DQ35598638-E145D48B-0EA9-45BA-A0EC-5A0FA3084FA3Q35935435-29BBC013-6104-4C45-B144-4ACFB645CD8BQ35959246-C500E207-112F-44E7-AE7F-74C5F9834D8FQ36576519-855C4014-79EC-4272-9994-398FB307B616Q37318758-689676B7-4A82-41D2-8B99-4C805A8549DCQ37420871-FD8F26E2-5995-4A5C-8D9A-566844276A2EQ38205213-7859B207-A8F2-41AF-824D-8C56969551D5Q38391129-560074AE-6A71-4C53-931C-6B3D354C7073Q38967851-244BDE67-E5B6-4052-9B3C-389B21F2D2FDQ39676339-83A62F63-C695-4753-AA7A-D9B41E5DC6CEQ41879572-7DC034F8-D0B7-4B9B-9E94-25E2EEE25C66Q42864618-8AA5CB4C-A2A3-474D-B60A-EE6CFFBD66DDQ43998698-570AF266-A30C-48F7-A56B-441146F666B4Q46001140-6BD75544-EBEA-4D1B-9F15-FE9581C792A3Q51551934-FF4DF741-98E8-40EE-B083-ECB47007C082Q59318878-019B5F45-DB96-45AC-9C49-E918F45CF471
P2860
Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Impact of the therapy by renin ...... ate in essential hypertension.
@en
Impact of the therapy by renin ...... ate in essential hypertension.
@nl
type
label
Impact of the therapy by renin ...... ate in essential hypertension.
@en
Impact of the therapy by renin ...... ate in essential hypertension.
@nl
prefLabel
Impact of the therapy by renin ...... ate in essential hypertension.
@en
Impact of the therapy by renin ...... ate in essential hypertension.
@nl
P2093
P2860
P356
P1476
Impact of the therapy by renin ...... ate in essential hypertension.
@en
P2093
H Kratochvíl'ová
P2860
P2888
P304
P356
10.1038/SJ.JHH.1002328
P577
2008-02-28T00:00:00Z